Recent Updates
Recently added Catalysts
EUDA Positive Sentiment

EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement

Key Takeaway: EUDA Health Holdings Limited announced a securities purchase agreement with Streeterville Capital for a convertible warrant worth $100,000. This warrant allows for the acquisition of up to 2 million shares at $6 each and is part of the company's strategy to boost capital for growth initiatives. CEO Alfred Lim emphasized the financing's role in expanding EUDA's footprint in the non-invasive healthcare market across Asia, targeting a demographic with changing healthcare needs.
Price reaction · baseline $58 (2025-12-04 close) · hit after-hours · 1 other EUDA headline(s) in the window, move may be shared
day 0 close
-6.2%
day 1
+1.7%
day 3 · peak
-26.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • EUDA entered a securities purchase agreement for $100,000, enhancing its capital position.
  • The financing allows for deployment into high-return initiatives like new centers and partnerships.
  • CEO highlights the potential for long-term value creation through disciplined execution and strategic growth.

Full Press Release Details

Health Holdings Limited Announces Execution of Securities Purchase Agreement
Dec. 05, 2025 (GLOBE NEWSWIRE) - EUDA Health Holdings Limited (NASDAQ: EUDA) ("EUDA" or "the Company"),
a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it entered
into a securities purchase agreement on November 26, 2025 with Streeterville Capital, LLC, a Utah limited liability company, for the
sale of a convertible warrant (the "Warrant") for an aggregate purchase price of US$100,000. The Warrant is exercisable for
up to 2,000,000 newly issued EUDA ordinary shares (the "Warrant Shares") at an exercise price of US$6.00 per share and is
being offered pursuant to the Company's effective shelf registration statement on Form F-3 (File No. 333-282723) and a related
prospectus supplement.
Capital is an investment firm with operations in Utah and Tennessee with investments in companies including Cingulate, the Marygold Companies
Warrant may be exercised for cash for ninety (90) days from the date of issuance, subject to extension by mutual agreement between the
Company and Streeterville Capital (the "Cash Exercise Period"). During the Cash Exercise Period, the Warrant may only be
exercised for cash, and the Company will have the right to require Streeterville Capital to exercise the Warrant, up to 10% of the cumulative
dollar trading volume during a measurement period, if (i) the closing price of the Company's ordinary shares on Nasdaq is at or
above US$7.50 for five (5) consecutive trading days and (ii) the cumulative trading dollar volume over that period is at least US$1,500,000.
Alfred Lim, CEO of EUDA, commented, "This agreement represents another deliberate step in strengthening our capital position
and advancing EUDA's growth strategy. The warrant financing gives us the flexibility to deploy capital into high-return initiatives
- including new centers, partnerships and technology - as we broaden our footprint across Asia's fast-growing non-invasive
healthcare market. By combining prudent financing with disciplined execution, we aim to accelerate the expansion of our healthcare ecosystem
while creating long-term value for our patients, partners and shareholders."
EUDA Health Holdings Limited
Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore,
Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the
fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which
is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and
science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment
to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words,
such as the words "estimates," "projected," "expects," "envisions," "anticipates,"
"forecasts," "plans," "intends," "believes," "seeks," "may,"
"will," "should," "future," "propose" and variations of these words or similar expressions
(or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions
or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are
outside EUDA's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking
statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document.
The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.

Frequently Asked Questions

What did EUDA announce on December 5, 2025?

EUDA announced a securities purchase agreement for a convertible warrant.

What is the total purchase price for the warrant?

The total purchase price for the warrant is US$100,000.

Who is the company EUDA partnering with?

EUDA is partnering with Streeterville Capital, LLC.

What is the purpose of the warrant financing?

The financing aims to strengthen capital and fund high-return initiatives.

How many shares can the warrant be exercised for?

The warrant is exercisable for up to 2,000,000 EUDA ordinary shares.

Last updated: Dec 5, 2025